Appointment of Independent Non-Executive Director

IXICO plc

05 October 2023

 

5 October 2023

IXICO plc

("IXICO" or the "Company")

Appointment of Independent Non-Executive Director

IXICO plc (AIM: IXI), the medical imaging advanced analytics company delivering insights in neuroscience, is pleased to announce the appointment of Dr Dipti Amin as an Independent Non-Executive Director of the Company with immediate effect.

Dr Amin is an experienced non-executive director and medically trained senior executive with extensive commercial, leadership and operational experience, in medicine, pharmacology and the highly regulated healthcare and research sectors.

Dr Amin spent over twenty years of her executive career at IQVIA, occupying senior positions in compliance, drug safety and medical affairs and will bring significant additional pharmaceutical and CRO experience to the Company.

Dr Amin currently sits on the Boards of the University of Hertfordshire and Lineage Cell Therapeutics, a US based biotechnology company, having previously sat on the Boards of companies in both the private and public sectors.

Dr Amin will also be joining the Remuneration and Audit committees with immediate effect.

Charles Spicer, Chair of IXICO, commented:

"We are delighted to welcome Dipti to our Board and look forward to benefitting from her broad and deep experience of both the pharmaceutical and CRO sectors."

For further information please contact: IXICO plc [phone] Giulio Cerroni, Chief Executive Officer Grant Nash, Chief Financial Officer Cavendish Securities PLC (Nominated adviser and sole broker) [phone] Giles Balleny / Charlie Combe (Corporate Finance) Michael F Johnson / Tamar Cranford Smith (Sales) About IXICO IXICO is dedicated to delivering insights in neuroscience to help transform the advancement of investigational therapies for neurological diseases, such as Huntington's disease, Parkinson's disease and Alzheimer's disease. The Company's purpose is to advance medicine and human health by turning data into clinically meaningful information, providing valuable new insights in neuroscience by supporting pharmaceutical companies across all phases of CNS clinical research. IXICO's goal is to be a leading advocate of artificial intelligence in medical image analysis. IXICO has developed and deployed breakthrough data analytics, at scale, through its remote access technology platform, to improve the return on investment in drug development and reduce risk and uncertainty in clinical trials for the Company's pharmaceutical clients. More information is available on www.IXICO.com and follow us on Twitter @IXICOnews Pursuant to Schedule 2 (g) of the AIM Rules for Companies, Dipti Mahendra Amin (Patel), aged 59, holds or has held the following directorships or partnerships in the past five years: Current Previous Lineage Cell Therapeutics University of Hertfordshire Buckinghamshire Healthcare NHS Trust Cambridge Innovation Capital Limited Maaya Associates Limited Dr Amin does not currently hold any shares in the Company. There is no further information required to be disclosed in respect of the above appointment pursuant to Rule 17 and Schedule 2 (g) of the AIM Rules for Companies.

 

END